Nanobiotix SA

5NR

Company Profile

  • Business description

    Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.

  • Contact

    60 Rue de Wattignies
    Paris75012
    FRA

    T: +33 140260470

    https://www.nanobiotix.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    108

Stocks News & Analysis

stocks

10 best US dividend aristocrats to buy now—including a surprise outperformer

These undervalued stocks with wide and narrow moats have increased their dividends for 25 consecutive years or more.
stocks

Leading ASX players in this field look materially overvalued

We raise our Fair Value estimates but still think that current share prices rely on overly optimistic expectations.
stocks

After earnings, is Alphabet stock a buy, a sell, or fairly valued?

With a diverse portfolio of innovative technology and integrated media platforms, here’s what we think of Alphabet’s stock.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,999.0016.40-0.18%
CAC 407,878.1016.140.21%
DAX 4024,395.74133.520.55%
Dow JONES (US)44,461.28171.71-0.38%
FTSE 1009,166.4329.490.32%
HKSE24,773.33403.60-1.60%
NASDAQ21,129.6731.380.15%
Nikkei 22541,069.82415.121.02%
NZX 50 Index12,823.7432.23-0.25%
S&P 5006,362.907.96-0.12%
S&P/ASX 2008,742.8013.60-0.16%
SSE Composite Index3,573.2142.51-1.18%

Market Movers